While much has been learned about SARS-CoV-2 since December of 2019, uneven global
vaccine distribution, rapid viral spread and variant evasion of preventative measures has led …

Emerging respiratory viruses are major health threats due to their potential to cause massive
outbreaks. Over the past 2 years, the coronavirus disease 2019 (COVID-19) pandemic has …

Here, we report a case of atopic dermatitis (AD) in a patient who received biweekly doses of
dupilumab, an antibody against the IL-4 receptor α chain (IL-4Rα). Single cell RNA …

The aim of this meta‐analysis is to evaluate the safety of dupilumab use in the management
of atopic dermatitis (AD) during the current pandemic regarding the risk and the hazards of …

Coronavirus disease 2019 (COVID-19) is a highly contagious viral disease caused by
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It has various effects on …

We previously found that type 2 immunity promotes coronavirus disease 2019 (COVID-19)
pathogenesis in a mouse model. To test relevance to human disease, we used electronic …

Objective Provide a review of atopic dermatitis management, focusing on optimizing topical
therapy, creating a stepwise approach for treatment plans, and providing guidance on when …

Biologics or molecularly targeted drugs are often highly effective for the treatment of allergic
diseases and other immunologic disorders, and they are relatively safe for short-term use as …

Dupilumab, an IL4R-blocking antibody, has shown clinical efficacy for atopic dermatitis (AD)
treatment. In addition to conjunctivitis/blepharitis, the de novo appearance of head/neck …

Background Based on studies implicating the type 2 cytokine interleukin 13 (IL-13) as a
potential contributor to critical coronavirus disease 2019 (COVID-19), this trial was designed …